Perspectives of People With HIV 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World US Study (BEYOND)

Conference Reports for NATAP

ID Week
Oct 11-15 2023
Boston, MA


Perspectives of People With HIV 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World US Study (BEYOND)

	ID Week Oct 11 2023